Risk factors for lipodystrophy in the CISAI cohort.
OBJECTIVE
This study set out to describe the frequency of lipodystrophy, and identify its risk factors, in HIV-positive patients treated with HAART containing at least one protease inhibitor (PI). We analyzed the data collected in the CISAI study.


METHODS
The CISAI is a multicenter cohort study that has enrolled 1480 patients. We assessed whether patients had lipodystrophy at a medical visit, with follow-up visits by the same physician at least every 2 months, and also on the basis of patients' own reports.


RESULTS
The lipodystrophy syndrome was detected in about 25% of the patients. Multivariate analysis showed the risk of lipodystrophy was correlated with female sex (RR 1.5; 95% confidence interval, CI, 1.2-2.1), with older age, with homosexuality (RR 1.5; 95% CI 1.0-2.4), with overt disease (RR 1.4; 95% CI 1.1-1.8) and with the duration of treatment before entering this study. The RR for ritonavir was higher than for the other PI (RR 1.4; 95% CI 0.9-1.9). Among patients receiving concomitant antiretroviral therapy the risk of lipodystrophy was greater with stavudine (RR 1.7; 95% CI 1.3-2.3).


CONCLUSIONS
The study confirmed the high frequency of the lipodystrophy syndrome among patients treated with PI.
Bonfanti
Paolo
P
I Divisione Malattie Infettive, Ospedale Luigi Sacco, Via GB Grassi 74, 20157, Milan, Italy. paolo.bonfanti@tin.it
Gulisano
Cecilia
C
Ricci
Elena
E
Timillero
Lia
L
Valsecchi
Laura
L
Carradori
Silvia
S
Pusterla
Luigi
L
Fortuna
Paolo
P
Miccolis
Sebastiano
S
Magnani
Carlo
C
Gabbuti
Andrea
A
Parazzini
Fabio
F
Martinelli
Canio
C
Faggion
Ivano
I
Landonio
Simona
S
Quirino
Tiziana
T
Vigevani
GianMarco
G
D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000188:drug therapy; D000328:Adult; D000367:Age Factors; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D005260:Female; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced*; D008297:Male; D012307:Risk Factors
D017320:HIV Protease Inhibitors